Enzolytics, Inc. is a drug development company. The Company is focused on commercializing its licensed proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted areas of sales, marketing and distribution of medical devices, medical testing and nutraceutical products. Its subsidiaries include BioClonetics lmmunotherapy, Inc. and Biogenysis, Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-02	US$0.000900	-10.00%	14,922,276
26-07-01	US$0.001000	0.00%	7,037,661
26-06-30	US$0.001000	0.00%	2,434,488
26-06-29	US$0.001000	0.00%	4,383,503
26-06-26	US$0.001000	0.00%	3,498,279

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 15:56:36 2026-07-02 EDT			5-day change	1st Jan Change
0.000900 ^USD	-10.00%		-10.00%	+200.00%

24-07-31	Enzolytics, Inc. and the Bulgaria Academy of Sciences Initiate A Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/A Applications	CI
24-07-29	Enzolytics, Inc. Enters into Collaboration Agreement with Manufacturer Elimus Ltd	CI

Market Cap	132K 116K 106K 99.01K 188K 12.59M 191K 1.28M 496K 6.19M 496K 486K 21.32M	P/E 2009 *	-	P/E 2010	-0.29x
Enterprise Value	460K 402K 369K 344K 653K 43.79M 663K 4.44M 1.72M 21.52M 1.73M 1.69M 74.17M	EV / Sales 2009	325,315,067x	EV / Sales 2010	210,445,953x
Free-Float	100%	Yield 2009 *	-	Yield 2010	-

24-07-31	Enzolytics, Inc. and the Bulgaria Academy of Sciences Initiate A Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/A Applications	CI
24-07-29	Enzolytics, Inc. Enters into Collaboration Agreement with Manufacturer Elimus Ltd	CI
24-05-02	Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment LLC	CI
24-03-25	Enzolytics, Inc. Announces Board Changes	CI
24-03-25	Enzolytics, Inc Appoints Diana Zhabilov as Chief Financial Officer	CI
24-03-25	Enzolytics, Inc Appoints Steven Sharabura as Chief Executive Officer	CI
23-06-26	Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project	CI
23-04-21	Enzolytics, Inc. Provides Update on Clinical Trials	CI
23-04-16	Biogenysis, Inc. & Virogentics, Inc. executed a non-binding term sheet to acquire Sagaliam Acquisition Corp. from Lighthouse Investment Partners, LLC, Enzolytics, Inc., Sagaliam Sponsor LLC, GLD Sponsor Member, LLC, AHG Equities LLC and others for $450 million in a reverse merger transaction.	CI
23-02-08	Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa	CI
23-01-03	Enzolytics to Develop Feline Monoclonal Antibodies	CI
22-12-13	Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms	CI
22-11-16	Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune	CI

24-08-05	Penny Stocks to Watch August 2024: SPZI, RJDG, HIRU, AABB more inside...	AQ
24-03-28	Stocks Under 5¢ Watch Now! CLNV, HNRC, HALB, ENZC, RSHN	AQ
24-03-12	RushNet (OTC: RSHN) and Royal Caridea Join Forces to Transform Aquaculture Harvesting Shrimp and more...SPZI, HALB, ENZC, HNRC	AQ
24-03-01	Stocks Under 5¢ To Watch Now! HNRC, HALB, ENZC, SNNC, SPZI	AQ
24-02-07	OTC Stocks to Watch in February: CLNV, HNRC, ENZC, GEVI, PBIO	AQ

Enzolytics, Inc. Stock

Stocks

ENZC

US2941121079

Biotechnology & Medical Research

Valuation: Enzolytics, Inc.

Chart: Enzolytics, Inc.

Latest news : Enzolytics, Inc.

Press Releases: Enzolytics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Enzolytics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 day	-10.00%
1 week	-10.00%
Current month	-10.00%
1 month	-10.00%
3 months	+125.00%
6 months	+200.00%
Current year	+200.00%

Manager	Title	Age	Since
Steven Sharabura CEO	Chief Executive Officer	-	2024-03-20
Diana Zhabilov DFI	Director of Finance/CFO	-	2024-03-20
Harry Zhabilov CEO	Chief Executive Officer	59	2017-06-15

Director	Title	Age	Since
Harry Zhabilov CHM	Chairman	59	2024-03-18
Lachezar Ivanov BRD	Director/Board Member	-	2024-03-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENZOLYTICS, INC.	-10.00%	-10.00%	+50.00%	-98.04%	4.35M
ARGENX SE	+0.68%	+5.92%	+80.45%	+137.78%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.51%	+94.88%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+45.58%	-1.42%	19.69B
GENMAB A/S	-0.29%	+9.78%	+44.62%	-27.94%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+178.93%	+360.74%	16.22B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	14.04B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+42.82%	-	14.84B
Average	+1.58%	+6.71%	+54.17%	+120.69%	24.55B
Weighted average by Cap.	+2.46%	+6.47%	+59.06%	+137.70%

	2009	2010
Net sales	0.01 0.01 0.01 0.01 0.02 1.4 0.02 0.14 0.06 0.69 0.06 0.05 2.37	0.04 0.03 0.03 0.03 0.05 3.52 0.05 0.36 0.14 1.73 0.14 0.14 5.96
Net income	-970K -848K -779K -726K -1.38M -92.34M -1.4M -9.35M -3.64M -45.39M -3.64M -3.56M -156M	-7.51M -6.57M -6.04M -5.63M -10.67M -715M -10.83M -72.47M -28.17M -352M -28.2M -27.6M -1.21B
Net Debt	924K 808K 742K 692K 1.31M 87.95M 1.33M 8.91M 3.46M 43.23M 3.47M 3.39M 149M	328K 286K 263K 245K 465K 31.2M 472K 3.16M 1.23M 15.34M 1.23M 1.2M 52.85M